Finance

Lists
Why is UNCY down 5,27%?
Dive Deeper
UNCY:NASDAQ
Unicycive Therapeutics Inc
4,31 US$
-5,27%
(-0,24) 1D
2 ოქტ, 10:19:32 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for UNCY...
Open
4,62 US$
High
4,62 US$
Low
4,30 US$
Mkt. cap
120,06 მლნ.
Avg. vol.
831,72 ათ.
Volume
154,91 ათ.
52-wk high
8,74 US$
52-wk low
3,93 US$
EPS
-1,62 US$
Beta
1,83
Shares outstanding
27,86 მლნ.
No. of employees
22
Open
4,62 US$
High
4,62 US$
Low
4,30 US$
Mkt. cap
120,06 მლნ.
Avg. vol.
831,72 ათ.
Volume
154,91 ათ.
52-wk high
8,74 US$
52-wk low
3,93 US$
EPS
-1,62 US$
Beta
1,83
Shares outstanding
27,86 მლნ.
No. of employees
22
News stories
From web sources and news partners
About Unicycive Therapeutics Inc
CEO-
Employees22
Founded2016
Headquarters-
Sector-
Websiteunicycive.com
Analyst ratings
Based on 6 analysts giving stock ratings to UNCY in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for UNCY in the last 3 months.
Highest
Current 4,31 US$
50,00 US$ (+1 060,09%)
Average
25,50 US$ (+491,65%)
Lowest
13,00 US$ (+201,62%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
13,00 US$
+201,6%
09/30/2026
Bruce Jackson
StoneX
Buy
Maintained
15,00 US$
+248%
08/20/2026
Jason McCarthy
Maxim Group
Buy
Maintained
30,00 US$
+596,1%
08/17/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
20,00 US$
+364%
08/13/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
50,00 US$
+1 060,1%
08/13/2026
Vamil Divan
Guggenheim
Buy
Maintained
25,00 US$
+480%
08/12/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
90,00 US$
+1 988,2%
06/01/2026
Unknown Analyst
Westpark Capital
Buy
Initiated
72,00 US$
+1 570,5%
02/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
2,96 მლნ.
2,25 მლნ.
1,61 მლნ.
2,79 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,38 მლნ.
4,97 მლნ.
6,83 მლნ.
7,35 მლნ.
Operating expense
7,34 მლნ.
7,22 მლნ.
8,44 მლნ.
10,14 მლნ.
Total operating expenses
7,34 მლნ.
7,22 მლნ.
8,44 მლნ.
10,14 მლნ.
Operating income
-7,34 მლნ.
-7,22 მლნ.
-8,44 მლნ.
-10,14 მლნ.
Other non operating income
1,07 მლნ.
-7,77 მლნ.
-4,78 მლნ.
7,98 მლნ.
EBT including unusual items
-6,01 მლნ.
-14,67 მლნ.
-12,82 მლნ.
-1,72 მლნ.
EBT excluding unusual items
-6,01 მლნ.
-14,67 მლნ.
-12,82 მლნ.
-1,72 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-6,01 მლნ.
-14,67 მლნ.
-12,82 მლნ.
-1,72 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,33
-0,82
-0,54
-0,06
Interest and investment income
279,00 ათ.
351,00 ათ.
394,00 ათ.
441,00 ათ.
Interest expense
-15,00 ათ.
-27,00 ათ.
-
-
Net interest expenses
264,00 ათ.
324,00 ათ.
394,00 ათ.
441,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-7,33 მლნ.
-7,21 მლნ.
-8,43 მლნ.
-10,13 მლნ.
Gain or loss from assets sale
-
-
18,00 ათ.
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები